Federal IDR outcomes: Intraoperative neuromonitoring in Oklahoma
In 2025 Q1–Q4, the provider or facility offer prevailed in 91.2% of 5,791 determined Federal IDR dispute line items for intraoperative neuromonitoring in Oklahoma. The median prevailing offer was 71.72x the QPA (25th–75th percentile 23.00x–136.57x; n = 4,798). The median time to a decision was 31 business days (n = 5,791).
Determined line items
5,791
2025 Q1–Q4 · 10 split decisions excluded
Provider win rate
91.2%
n = 5,791 · 2025 Q1–Q4
Median days to decision
31
business days, from dispute initiation · n = 5,791 · 2025 Q1–Q4
Dollar amounts are not shown for specialty groups: the CMS QPA and Offers file, the only source of dollar figures, has no specialty field. See methodology.
By period
| Period | Line items | Win % | Median ×QPA | 25th–75th | Ratio n | Median days |
|---|---|---|---|---|---|---|
| 2025 Q1–Q4 | 5,791 | 91.2% | 71.72x † | 23.00x–136.57x | 4,798 | 31 |
| 2024 Q1–Q4 | 2,523 | 92.7% | 45.88x † | 14.62x–106.71x | 2,025 | 40 |
| 2023 Q1–Q4 | 125 | 56.0% | 6.71x | 1.00x–34.34x | 35 | 82 |
| 2023 Q1–2025 Q4 | 8,439 | 91.1% | 61.03x † | 19.92x–124.95x | 6,858 | not pooled |
Line items = determined dispute line items (n). Win rate excludes split decisions and includes default decisions. Ratio n = line items reporting a payment-to-QPA ratio. Days are business days as reported by CMS (2023–2024: from IDR entity assignment; 2025: from initiation) and are never pooled.
Most disputed CPT codes
| CPT code | Line items | Win % | Median ×QPA | Ratio n | Median days |
|---|---|---|---|---|---|
| 95938 Placement of skin electrodes and measurement of stimulated sites on arms and leg | 1,235 | 91.2% | 136.07x † | 1,036 | 31 |
| 95941 Continuous remote monitoring of nervous system during operation, each hour | 665 | 94.1% | 58.85x † | 563 | 28 |
| 95955 Measurement of brain wave activity (EEG) outside the brain during surgery | 610 | 94.3% | 122.17x † | 495 | 33 |
| 95939 Placement of skin electrodes and measurement of central motor stimulation in arm | 545 | 90.5% | 47.39x † | 422 | 30 |
| 95937 Testing of nerve-muscle junction | 516 | 95.0% | 93.60x † | 491 | 31 |
| 95870 Needle measurement of electrical activity in arm, leg, trunk or head muscles, li | 493 | 89.9% | 152.71x † | 401 | 32 |
| 95861 Needle measurement of electrical activity in arm or leg muscles, 2 extremities | 278 | 84.5% | 49.19x † | 215 | 31 |
| 95885 Needle measurement of electrical activity in arm or leg muscles, limited study | 160 | 94.4% | 108.38x † | 152 | 28 |
| 95868 Needle measurement of electrical activity in muscles on both sides of body | 159 | 92.5% | 90.74x † | 126 | 36 |
| 95908 Nerve conduction, 3-4 studies | 112 | 96.4% | 37.47x † | 107 | 27 |
| 95940 Continuous monitoring of nervous system during operation, each 15 minutes | 97 | 90.7% | 25.26x † | 45 | 28 |
| 95957 Measurement of brain wave activity (EEG), digital analysis | 73 | 84.9% | 13.30x | 72 | 27 |
| 95813 Measurement of brain wave activity (EEG), 61-119 minutes | 60 | 96.7% | 47.23x † | 59 | 31 |
| 95865 Needle measurement of electrical activity in voice box muscles | 59 | 84.7% | 68.44x † | 31 | 27 |
| 95909 Nerve conduction, 5-6 studies | 52 | 94.2% | 40.68x † | 49 | 27.5 |
| 95927 Placement of skin electrodes and measurement of stimulated sites in trunk or hea | 47 | 87.2% | – | 23 | 39 |
| 95886 Needle measurement of electrical activity in arm or leg muscles, complete study | 44 | 95.5% | 57.86x † | 43 | 30 |
| 95822 Measurement of brain wave activity (EEG), in coma or asleep | 41 | 92.7% | – | 27 | 26 |
| 95907 Nerve conduction, 1-2 studies | 41 | 90.2% | 42.23x † | 39 | 26 |
| 95867 Needle measurement of electrical activity in muscles on side of body | 33 | 93.9% | – | 24 | 26 |
2025 Q1–Q4 · rows with n ≥ 30 determined line items · sorted by n.
Related: all specialties in Oklahoma · Intraoperative neuromonitoring in all states
FAQ
What is the Federal IDR provider win rate for intraoperative neuromonitoring in Oklahoma?
In 2025 Q1–Q4, the provider or facility offer was selected in 91.2% of 5,791 determined dispute line items for intraoperative neuromonitoring in Oklahoma. Split decisions are excluded from the denominator and default decisions are included. Withdrawn, settled and ineligible disputes are not in the CMS data.
How do Federal IDR payments compare with the QPA for intraoperative neuromonitoring in Oklahoma?
In 2025 Q1–Q4, the median prevailing offer was 71.72x the qualifying payment amount (QPA), with a 25th to 75th percentile range of 23.00x to 136.57x (n = 4,798 line items). This uses the CMS field Prevailing Party Offer as % of QPA, where 1.00x equals the QPA.
How long do Federal IDR decisions take for intraoperative neuromonitoring in Oklahoma?
In 2025 Q1–Q4, the median was 31 business days (n = 5,791 line items), using the CMS field Length of Time to Make Determination (from dispute initiation).